Letter to Gilead Sciences Regarding the Emergency Use Authorization Granted by the FDA for Remdesivir

View as PDF

View press release

Public Citizen urged Gilead Sciences to immediately either (a) release the data regarding the safety and efficacy of remdesivir on which the Food and Drug Administration (FDA) relied in granting the company’s Emergency Use Authorization request for emergency use of remdesivir for treatment of hospitalized COVID-19 patients, or (b) inform the FDA that the company consents to the FDA’s release of such information in response to a Freedom of Information Act request submitted by Public Citizen.

See Public Citizen’s other work on the coronavirus pandemic.